A Pregnancy That Is Not: Molar Pregnancy and Gestational Trophoblastic Disease
An early scan is meant to show a fetus. Sometimes it shows something else. The word that follows is one most people have never heard applied to a pregnancy: molar. A second one follows, trophoblastic, on a page that mentions cancer. The diagnosis does not land in one piece either. It comes as an ultrasound report, then a line of histology after the uterus is emptied, then a column of hCG numbers with dates beside them. Holding those three as one case instead of three phone calls is what Healz's memory is for.
This post follows the condition in the order it reaches a person: what gestational trophoblastic disease covers, how a complete mole differs from a partial one, what the scan can suggest and what only the histology settles, and why the blood test after evacuation decides everything. Most moles are benign. The surveillance afterwards is what finds the minority that are not.

What the words on the report actually cover
Gestational trophoblastic disease is a family, not a single diagnosis, and its two halves behave very differently. On one side sit the hydatidiform moles, complete and partial. On the other sits gestational trophoblastic neoplasia, which the NCI PDQ health professional summary lists as invasive mole, choriocarcinoma, placental site trophoblastic tumour and epithelioid trophoblastic tumour. The same summary calls the placental site tumour very rare and the epithelioid tumour extremely rare; those two and choriocarcinoma are often grouped as gestational trophoblastic tumours.
That split is why the paperwork reads so alarmingly. Most hydatidiform moles are benign, and the PDQ health professional summary says they are treated conservatively by dilation, suction evacuation and curettage. Neoplasia is the malignant end of the same family, and everything that follows an evacuation exists to establish which side of the line a case has landed on. Nobody can tell on the day of the scan.
Ask Healz.
One chat instead of ten apps. 1M+ rare cases checked. The root cause, not the label. Private.
Why complete and partial are two different diagnoses
The two moles are separated by their genetics, and that is why one carries more risk. A complete mole is androgenetic and diploid, carrying two paternal copies of the genome, most often with a 46,XX karyotype, and complete moles show no evidence of fetal tissue (Kalogiannidis and colleagues, Journal of Assisted Reproduction and Genetics, 2018). A partial mole is a diandric triploid, one maternal set of chromosomes and two paternal, and unlike the complete form it does show fetal tissue. The PDQ health professional summary gives the partial karyotype as 69,XXY, 69,XXX or 69,XYY.
That difference carries straight through to risk. Per the PDQ health professional summary, complete moles have a 15% to 25% risk of developing into an invasive mole, while transformation to malignancy is much more rare in partial moles, under 5%, and the proportion needing chemotherapy for persistence or neoplastic transformation after evacuation runs about 15% to 20% for complete moles against fewer than 5% for partial ones. So the single word in the histology line, complete or partial, is not a detail of classification. It sets how closely the months afterwards are watched.
What the scan suggests and what the histology settles
Per the PDQ health professional summary, an hCG blood level and a pelvic ultrasound are the initial steps in the diagnostic evaluation. The classical presentation is vaginal bleeding and a rapidly enlarging uterus, with hyperemesis gravidarum, anaemia, hyperthyroidism and early preeclampsia also described there. On ultrasound, complete moles rarely reveal a fetus or amniotic fluid, while partial moles usually show a fetus, which may even be viable, with amniotic fluid visible.
The classical presentation is also no longer the usual one. In a Swedish review of 331 women with hydatidiform mole, complete and partial moles were diagnosed before the onset of symptoms in 32% and 53% of cases respectively, against a previously reported 10% (Joneborg and Marions, Journal of Reproductive Medicine, 2014). Early scanning moved the diagnosis forward, so many moles are now found on a dating scan by someone who feels entirely well.
The same study shows the limit of imaging. Ultrasound predicted the molar diagnosis in 73% of complete moles and 35% of partial moles in that series. A scan can raise the question convincingly, and in a third of partial moles it does not raise it at all. What names the diagnosis is examination of the tissue after the uterus is evacuated, which is why the pathology report, not the scan report, carries the answer. The same logic runs through other parts of gynaecology, and our piece on what an endometrial biopsy can and cannot settle follows it for abnormal bleeding.
The number that does the watching
Here is the part that matters most, and it is not a scan or an operation. It is a blood test, repeated. Per the PDQ health professional summary, patients must be followed carefully with weekly serum hCG levels to normalisation, and monthly follow-up for 6 months is generally recommended afterwards, though the summary notes that the duration of that phase is not based on empiric study.
The curve is the diagnosis. hCG should fall once the mole is removed; if it stops falling or climbs, the tissue producing it is still active. The PDQ health professional summary lists the findings that make chemotherapy necessary: a rising beta-hCG titre for 2 weeks across 3 titres, a plateau of the beta-hCG for 3 weeks, persistence of detectable beta-hCG 6 months after evacuation, an elevation after a normal value, a tissue diagnosis of choriocarcinoma, metastatic disease, and postevacuation haemorrhage not caused by retained tissue. The thresholds are specific. That summary defines the plateau as a beta-hCG decrease of 10% or less for 3 consecutive weeks, and a rise as an increase greater than 20% for 2 consecutive weeks.
Which is why one quiet instruction in the follow-up plan carries so much weight. The PDQ health professional summary states that an effective form of contraception is important during the follow-up period, to avoid the confusion that can occur with a rising beta-hCG as a result of pregnancy. A new pregnancy produces hCG too, so the one measurement that separates persistent disease from recovery stops meaning anything.
What happens when the curve does not fall
A plateau or a rise is not a treatment failure. It is the point at which the condition is reclassified as gestational trophoblastic neoplasia. Staging follows the uterus outward: the PDQ health professional summary gives FIGO stage I as strictly confined to the uterine corpus, stage II as extending to the adnexa or vagina but limited to the genital structures, stage III as extending to the lungs, and stage IV as all other metastatic sites.
Stage alone does not pick the treatment. A prognostic score does, and the summary separates treatment of low-risk disease at a FIGO score of 0 to 6 from high-risk disease at a score of 7 or above. For low-risk disease the summary names weekly methotrexate and biweekly dactinomycin among first-line options and states that ultimate cure rates are generally 99% or more. For high-risk disease it states that multiagent chemotherapy is standard for initial management, and reports a complete remission rate of 78% among 272 patients treated with the EMA/CO regimen.
Chemosensitivity is not uniform across the family, though. The same summary describes placental site trophoblastic tumours as generally resistant to chemotherapy and epithelioid trophoblastic tumours as not very responsive to systemic therapy, while invasive moles are treated like choriocarcinoma but, unlike choriocarcinoma, may regress spontaneously. So the headline that gestational trophoblastic neoplasia responds unusually well to chemotherapy holds for the common forms and not the rare ones, and the histological name decides which applies. hCG works as a tumour marker elsewhere in gynaecological oncology too, a pattern our piece on germ cell tumours in young women covers in its own context.
What one mole means for the next pregnancy
The arithmetic here is worth stating plainly. Per the PDQ health professional summary, a woman previously diagnosed with a hydatidiform mole carries a 1% risk of a mole in subsequent pregnancies, rising to approximately 25% with more than one prior mole. A 1% risk means the overwhelming majority of later pregnancies are not molar; the jump after a second is why a repeat is treated differently.
A raised hCG with no pregnancy to explain it always needs an explanation. The PDQ health professional summary makes that concrete by listing detectable beta-hCG 6 months after evacuation as a trigger for treatment in its own right: a number that should be zero and is not is a finding, not a loose end.
How Healz reads a molar pregnancy case
The ultrasound report, the histology wording and the hCG values with their dates belong in one place. In practice they arrive as a scan portal, a pathology letter and a run of phone calls, and nobody holds all three at once. Healz has memory, and that memory pulls the medical facts out of every upload: each hCG value with the date it was drawn, the complete or partial wording from the pathology report, abnormal results kept up front instead of buried on page four. The curve is visible as a curve, so a 10% drop across three weeks looks like what it is.
Frontier AI works the case in the same chat. Healz is equipped with root-cause technology, so it does not stop at the first label on the page: it asks what a rushed appointment skips, cross-checks the case against more than a million rare cases, and reads the histology line against the hCG trend instead of either one alone. Here the distinction between complete, partial and neoplasia is the whole case. One chat, not ten apps and three portals. You can bring a board-certified doctor into the same chat for a second opinion.
Frequently asked questions
- Is a molar pregnancy cancer?
Usually not. A hydatidiform mole sits on the benign side of gestational trophoblastic disease, and the NCI PDQ health professional summary says most moles are treated conservatively with dilation, suction evacuation and curettage. The malignant side of the same family is gestational trophoblastic neoplasia, which includes invasive mole and choriocarcinoma. Which one a case becomes is settled by the hCG curve after evacuation.
- What is the difference between a complete and a partial molar pregnancy?
The genetics, and then the risk. A complete mole is androgenetic and diploid with two paternal copies of the genome and no fetal tissue, while a partial mole is a diandric triploid with one maternal and two paternal chromosome sets and fetal tissue present (Kalogiannidis and colleagues, Journal of Assisted Reproduction and Genetics, 2018). Per the NCI PDQ health professional summary, complete moles carry a 15% to 25% risk of becoming an invasive mole, against under 5% for partial moles.
- Why are hCG levels checked every week after a molar pregnancy?
Because the trend is what detects persistent disease. The NCI PDQ health professional summary says hCG is followed weekly to normalisation, then monthly for 6 months. A plateau, defined there as a decrease of 10% or less across 3 consecutive weeks, or a rise greater than 20% across 2 consecutive weeks, is what defines post-molar neoplasia and leads to treatment. No single value carries that information.
- Can you get pregnant again after a molar pregnancy?
The NCI PDQ health professional summary puts the risk of a mole in a subsequent pregnancy at 1% after one mole, rising to approximately 25% after more than one. The same summary explains why reliable contraception during the surveillance period matters: a pregnancy raises hCG, and a rising hCG is the signal being watched for. Questions about timing belong with the clinician running the follow-up.
An early scan that shows something other than a pregnancy starts a diagnosis that no single document can finish, and the thing that finishes it is a line of numbers with dates attached, held together long enough to show which way they are going.
Written by Healz Team · Filed under Health Insights